𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A new approach to understand the pathophysiology of Parkinson’s disease

✍ Scribed by Atsushi Nambu

Publisher
Springer
Year
2005
Tongue
English
Weight
252 KB
Volume
252
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Milestones in research on the pathophysi
Milestones in research on the pathophysiology of Parkinson's disease
✍ Thomas Wichmann; Mahlon R. DeLong; Jorge Guridi; Jose A. Obeso 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 400 KB 👁 1 views

## Abstract Progress in our understanding of the mechanisms underlying the cardinal motor abnormalities of Parkinson's disease (PD), in particular akinesia and bradykinesia and their treatment, has been remarkable. Notable accomplishments include insights into the functional organization of the bas

Pathophysiology of Parkinson's disease:
Pathophysiology of Parkinson's disease: From clinical neurology to basic neuroscience and back
✍ Hagai Bergman; Günther Deuschl 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 255 KB

Parkinson's disease (PD) is characterized by motor and nonmotor (cognitive and limbic) deficits. The motor signs of PD include hypokinetic signs such as akinesia/bradykinesia, rigidity and loss of normal postural reflexes, and hyperkinetic signs such as tremor. Dopamine depletion in the striatum is

Oscillatory nature of human basal gangli
Oscillatory nature of human basal ganglia activity: Relationship to the pathophysiology of Parkinson's disease
✍ Peter Brown 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 265 KB

## Abstract Alterations of basal ganglia physiology in parkinsonism may consist of two elements, an increase in the firing rate of neurones and a change in the pattern of synchronisation of discharges between neurones. Recent findings suggest the presence of two principal modes of synchronised acti

An MCASE approach to the search of a cur
An MCASE approach to the search of a cure for Parkinson's Disease.
✍ Gilles Klopman; Aleksandr Sedykh 📂 Article 📅 2002 🏛 BioMed Central 🌐 English ⚖ 278 KB

Background: Parkinson's disease is caused by a dopamine deficiency state in the fore brain area. Dopamine receptor agonists, MAO-B inhibitors, and N-Methyl-D-Aspartate (NMDA) receptor antagonists are known to have antiparkinson effect. Levodopa, a dopamine structural analog, is the best currently av